close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

11.41 +0.93 (+8.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Day One Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Day One Announces Two New Appointments to Board of Directors
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting 
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Priority review granted with PDUFA target action date of April 30, 2024 
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Pricing of Public Offering of Common Stock
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Proposed Public Offering of Common Stock
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Participate in the Cowen 43rd Annual Health Care Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... 
Via FinancialNewsMedia
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today